OSE Immunotherapeutics

161 articles about OSE Immunotherapeutics

• OSE Immunotherapeutics Announces H1 2021 Results and Provides a Corporate Update

  9/21/2021

  Positive final Phase 3 results for Tedopi® in non-small cell lung cancer (NSCLC) after ICI failure.

• OSE Immunotherapeutics To Present Positive Results of Tedopi® Phase 3 Clinical Trial in Non-Small Cell Lung Cancer Patients in Secondary Resistance to Immune Checkpoint Inhibitors At the ESMO Virtual Congress 2021

  9/20/2021

  OSE Immunotherapeutics announces the presentation of Phase 3 clinical results of Tedopi® at 13:30 CEST in a late-breaking oral presentation at the European Society for Medical Oncology Virtual Congress.

• OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients

  9/20/2021

  OSE Immunotherapeutics today announced that the positive final results of its Phase 3 trial of neoepitope-based cancer vaccine Tedopi ® , called Atalante 1, in HLA-A2 positive patients with advanced non-small cell lung cancer

• 

  Clinical Catch-Up: September 13-17

  9/20/2021

  With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.

• Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021

  9/16/2021

  BI 765063, a first-in-class SIRPα inhibitor in the SIRPα/CD47 “Don’t eat me” pathway, is being developed under collaborative agreement between OSE Immunotherapeutics and Boehringer Ingelheim.

• 

  ESMO Preview: Highlights to Watch for This Year

  9/15/2021

  The European Society for Medical Oncology Congress 2021 runs from September 16–21, 2021. Here’s a preview of some of the presentations at the meeting.

• Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021

  9/13/2021

  OSE Immunotherapeutics SA announced that promising data from dose escalation Phase 1 of selective SIRPα inhibitor BI 765063 in patients with advanced solid tumors will be presented at the 2021 European Society for Medical Oncology Virtual Conference to be held on September 16 – 21, 2021.

• OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®

  9/7/2021

  OSE Immunotherapeutics announced that it has received notice of allowance from the United States Patent and Trademark Office for a patent application related to Tedopi®, a combination of neoepitopes, protecting its administration schedule for inducing early T-lymphocyte memory response, used in the treatment of non-small cell lung cancer in HLA-A2 positive patients.

• OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceSeptember 13 - 15, 2021 (Virtual Conference)

  9/1/2021

  OSE Immunotherapeutics (ISIN: FR0012127173) today announced it will present at the H.C. Wainwright 23 r d Annual Global Investment Conference. The conference is being held virtually on September 13 – 15, 2021.

• OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer

  8/26/2021

  OSE Immunotherapeutics announced today that the first patient has been randomized in the Phase 2 clinical trial evaluating Tedopi® alone and in combination with MSD’s Keytruda® (pembrolizumab) as maintenance treatment in patients with recurrent ovarian cancer after chemotherapy (the TEDOVA trial).

• Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

  8/25/2021

  Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a French biotech, have announced enrollment of the first patient in the Phase 2 clinical trial of OSE-127/S95011 in Sjögren’s syndrome, with Servier sponsorship.

• OSE Immunotherapeutics Announces Upcoming Investor Conferences and R&D Day

  8/24/2021

  OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the Company will be present at the following investor events: H.C. Wainwright 23rd Annual Global Investment Conference - September 13 - 15, 2021

• 

  Clinical Catch-Up: July 19-23

  7/26/2021

  It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more.

• OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study

  7/19/2021

  OSE Immunotherapeutics SA   today announced a voluntary and temporary pause of enrollment and dosing in its ongoing Phase 1 clinical trial for CoVepiT, the company’s investigational prophylactic COVID-19 vaccine candidate.

• OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank

  7/9/2021

  OSE Immunotherapeutics announced a €10 million payment corresponding to the first tranche of the financing granted by the European Investment Bank.

• OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine

  6/30/2021

  OSE Immunotherapeutics and Cenexi, a French contract development and manufacturing organization, announced the signature of an agreement whereby Cenexi will manufacture clinical batches of CoVepiT, OSE Immunotherapeutics' vaccine candidate against COVID-19 currently in Phase 1 clinical trial, which will be used in the product’s development phases.

• OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting

  6/24/2021

  OSE Immunotherapeutics announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.

• OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer

  5/27/2021

  OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and the FoRT Foundation (Fondazione Ricerca Traslazionale) today announced that the Italian Medicines Agency (AIFA) and the Italian Ethics Committee approved the initiation of a new Phase 2 clinical trial evaluating Tedopi® in combination with Opdivo® or chemotherapy as second-line treatment in patients with metastatic non-small cell lung cancer (NSCLC).

• OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine

  5/26/2021

  OSE Immunotherapeutics announced that the first healthy volunteer has been enrolled and dosed in the Phase 1 clinical trial evaluating its COVID-19 vaccine, named CoVepiT.

• OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with First-in-Class SIRPα inhibitor BI 765063 in Advanced Solid Tumors at ASCO 2021

  5/20/2021

  BI 765063, a first-in-class SIRPα inhibitor on the SIRPα/CD47 “Don’t eat me” pathway, is undercollaborative development with Boehringer Ingelheim.